Skip to content

Stevanato Group and Partners Revolutionize Large-Dose Drug Delivery for Chronic Patients

Chronic patients may soon say goodbye to painful injections. A breakthrough collaboration merges cutting-edge cartridge, stopper, and platform tech for smoother at-home treatments.

The image shows a pharmacy on the corner of a street, with glass walls and doors, posters on the...
The image shows a pharmacy on the corner of a street, with glass walls and doors, posters on the walls, and a road at the bottom.

Stevanato Group and Partners Revolutionize Large-Dose Drug Delivery for Chronic Patients

Stevanato Group has teamed up with Datwyler and LTS Device Technologies to enhance subcutaneous drug delivery. The collaboration centers on making large-dose injections—between 10 and 20 ml—more comfortable for patients. This move aligns with the rising demand for self-administered biologics, which is projected to reach $483 billion in the U.S. by 2034.

The three companies will combine their technologies to simplify drug administration. Stevanato Group supplies EZ-fill® cartridges, Datwyler provides custom plunger stoppers, and LTS Device Technologies integrates its Sorrel™ platform. Together, they aim to streamline high-volume injections for patients managing chronic conditions at home.

The biologics market growth, driven by increased self-medication for complex treatments, necessitates user-friendly delivery systems. To support this initiative, Stevanato Group recently expanded its Bad Oeynhausen facility in Germany by over 2,500 square meters. The upgrade includes new ISO Class 8 cleanrooms, boosting production capacity for both proprietary and contract-manufactured products. The company has also emphasized global scalability, though details on additional production sites remain undisclosed.

Financial updates on these efforts will be available soon. Stevanato Group plans to release its fourth-quarter 2025 results on March 5, offering insights into the profitability of its latest projects.

The partnership between Stevanato Group, Datwyler, and LTS Device Technologies targets easier administration of large drug doses. With expanded facilities and integrated technologies, the companies are positioning themselves for growth in the biologics sector. The upcoming financial report will reveal how these investments are performing.

Read also:

Latest